HPC Scalability Service for biomedical applications
2 March 2023
Users of computational biomedical applications are increasingly encountering performance issues, eg perhaps code cannot run in an acceptable time. CompBioMed’s free Scalability Service is designed to help.
EPCC is part of CompBioMed, a European Commission Centre of Excellence focused on the use and development of high performance computing (HPC) for biomedical applications. HPC can enhance industries in the healthcare sector including pharmaceuticals and medical device manufacturers.
CompBioMed now offers free support to organisations in their initial steps towards either parallelising their existing computational biomedical applications, or improving the scalability of those applications already parallelised, and thereafter deploy them on HPC platforms.
Its Scalability Service boosts the performance of biomedicine applications via a range of support routes, such as informal discussions about efficient use of parallel platforms in general and code reviews, to porting and profiling applications and suggesting improvements, or working closely with the client and adapting the source code on their behalf.
Please visit the CompBioMed website for more information, where you’ll also find links to a group email of experts in both HPC and biomedical applications, and access to the public Slack channel #scalability, hosted by “In Silico World” Community of Practice, which provides a safe space to share scaling questions. The website also proffers both a detailed application form and a more informal webform version.
The Scalability Service includes a live, useful overview for programmers with ideas on improving the performance of parallel applications for high-end supercomputers [3].
In the field of biomedicine, many applications deal with sensitive data, and clients can be assured that great care is taken when adapting their applications and managing the associated data. The data policies cover data privacy, data security, and research data management. See: compbiomed.eu/compbiomed-data-policies.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 675451 (phase 1) and grant agreement No. 823712 (phase 2).
Image courtesy CompBioMed.
